Aura Biosciences (AURA) Assets Average (2021 - 2026)
Aura Biosciences' (AURA) quarterly Assets Average came in at $153.6 million in Q1 2026, down 9.11% YoY from $169.0 million in Q1 2025, and down 14.56% on a QoQ basis from $179.7 million in Q4 2025.
Aura Biosciences (AURA) Assets Average (2021 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 6 years of Assets Average data on file, last reported at $153.6 million in Q1 2026.
- Quarterly Assets Average fell 9.11% year-over-year to $153.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153.6 million (down 9.11% YoY) and the FY2025 annual result came in at $176.0 million, down 19.57% from the prior year.
- Assets Average retreated to $153.6 million in Q1 2026, from $179.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $245.0 million in Q1 2024 to a low of $139.1 million in Q3 2022.
- A 5-year average of $187.7 million and a median of $186.3 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average soared 46.4% — and 2025, when it slumped 31.05%.
- Tracing AURA's Assets Average over 5 years: stood at $183.5 million in 2022, then advanced by 18.46% to $217.4 million in 2023, then fell by 10.81% to $193.9 million in 2024, then decreased by 7.32% to $179.7 million in 2025, then decreased by 14.56% to $153.6 million in 2026.
- The last three Assets Average figures came in at $153.6 million (Q1 2026), $179.7 million (Q4 2025), and $197.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | 242.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 242.90 Mn |
| Mar 31, 2026 | 153.55 Mn |
| Dec 31, 2025 | 179.73 Mn |
| Sep 30, 2025 | 197.21 Mn |
| Jun 30, 2025 | 179.90 Mn |
| Mar 31, 2025 | 168.95 Mn |
| Dec 31, 2024 | 193.92 Mn |
| Sep 30, 2024 | 211.81 Mn |
| Jun 30, 2024 | 226.65 Mn |
| Mar 31, 2024 | 245.05 Mn |
| Dec 31, 2023 | 217.42 Mn |
| Sep 30, 2023 | 186.25 Mn |
| Jun 30, 2023 | 199.38 Mn |
| Mar 31, 2023 | 214.98 Mn |
| Dec 31, 2022 | 183.54 Mn |
| Sep 30, 2022 | 139.08 Mn |
| Jun 30, 2022 | 140.72 Mn |
| Mar 31, 2022 | 153.23 Mn |
| Dec 31, 2021 | 125.37 Mn |